PDE3A

Across TCGA pan-cancer cohorts, PDE3A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PDE3A data layer compared with 23 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PDE3A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PDE3A expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, LSCC, and UCEC are the cancer types where PDE3A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	1.000	0.537	.008	16	view →
LSCC	DFS	Quartile	II,III,IV	0.752	1.000	.009	7	view →
UCEC	OS	Tertile	All	0.828	0.968	.024	2	view →
HNSC	OS	Median	IV	0.971	0.784	.038	2	view →
CCRCC	OS	Median	III,IV	0.907	0.733	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PDE3A–PDAC (OS)

Open the PDAC breakdown →